Spinal cord damage in multiple sclerosis often leads to the formation of inflammatory lesions. APT CEST has been proposed as an MRI biomarker capable of detecting the underlying biochemical changes associated with lesion formation, however, CEST findings are susceptible to confounding influences such as the macromolecular magnetization transfer contribution and changes to longitudinal relaxation. AREX is a proposed method which corrects for these contributors and may improve measurement of the CEST component in vivo. In this study we sought to compare MT- and T1-corrected AREX to an uncorrected CEST quantification method in SC lesions of MS patients.
This abstract and the presentation materials are available to members only; a login is required.